サンバイオの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/10/24 | 1,009 | 1,018 | 986 | 994 | -31 | -3% | 787,100 |
| 2024/10/23 | 1,042 | 1,056 | 1,013 | 1,025 | +3 | +0.3% | 535,600 |
| 2024/10/22 | 1,041 | 1,049 | 1,013 | 1,022 | -18 | -1.7% | 446,900 |
| 2024/10/21 | 1,044 | 1,075 | 1,037 | 1,040 | +5 | +0.5% | 643,600 |
| 2024/10/18 | 1,031 | 1,036 | 1,020 | 1,035 | +6 | +0.6% | 424,300 |
| 2024/10/17 | 1,040 | 1,058 | 1,029 | 1,029 | -17 | -1.6% | 556,500 |
| 2024/10/16 | 1,040 | 1,058 | 1,024 | 1,046 | -11 | -1% | 556,200 |
| 2024/10/15 | 1,055 | 1,083 | 1,051 | 1,057 | -12 | -1.1% | 642,700 |
| 2024/10/11 | 1,114 | 1,120 | 1,066 | 1,069 | -62 | -5.5% | 1,079,100 |
| 2024/10/10 | 1,112 | 1,150 | 1,095 | 1,131 | +21 | +1.9% | 1,167,800 |
| 2024/10/09 | 1,159 | 1,186 | 1,097 | 1,110 | -48 | -4.1% | 1,585,100 |
| 2024/10/08 | 1,193 | 1,194 | 1,145 | 1,158 | -35 | -2.9% | 946,100 |
| 2024/10/07 | 1,204 | 1,210 | 1,169 | 1,193 | +7 | +0.6% | 1,019,800 |
| 2024/10/04 | 1,220 | 1,228 | 1,178 | 1,186 | -34 | -2.8% | 1,310,500 |
| 2024/10/03 | 1,316 | 1,320 | 1,220 | 1,220 | -59 | -4.6% | 2,727,400 |
| 2024/10/02 | 1,279 | 1,351 | 1,270 | 1,279 | -36 | -2.7% | 4,797,700 |
| 2024/10/01 | 1,155 | 1,363 | 1,153 | 1,315 | +162 | +14.1% | 5,800,600 |
| 2024/09/30 | 1,180 | 1,218 | 1,150 | 1,153 | -29 | -2.5% | 1,746,700 |
| 2024/09/27 | 1,206 | 1,247 | 1,175 | 1,182 | ±0 | ±0% | 2,026,800 |
| 2024/09/26 | 1,243 | 1,290 | 1,175 | 1,182 | -180 | -13.2% | 5,177,300 |
| 2024/09/25 | 1,245 | 1,385 | 1,212 | 1,362 | +124 | +10% | 11,443,500 |
| 2024/09/24 | 1,340 | 1,341 | 1,183 | 1,238 | -57 | -4.4% | 6,909,500 |
| 2024/09/20 | 1,133 | 1,319 | 1,099 | 1,295 | +213 | +19.7% | 11,772,900 |
| 2024/09/19 | 992 | 1,096 | 988 | 1,082 | +120 | +12.5% | 4,549,300 |
| 2024/09/18 | 922 | 980 | 915 | 962 | +22 | +2.3% | 1,211,000 |
| 2024/09/17 | 980 | 980 | 921 | 940 | -22 | -2.3% | 828,800 |
| 2024/09/13 | 978 | 981 | 944 | 962 | -7 | -0.7% | 582,000 |
| 2024/09/12 | 949 | 977 | 923 | 969 | +49 | +5.3% | 925,100 |
| 2024/09/11 | 950 | 952 | 905 | 920 | -37 | -3.9% | 1,198,000 |
| 2024/09/10 | 957 | 965 | 940 | 957 | +5 | +0.5% | 568,700 |
| 2024/09/09 | 893 | 963 | 882 | 952 | +14 | +1.5% | 1,019,600 |
| 2024/09/06 | 1,018 | 1,036 | 932 | 938 | -33 | -3.4% | 3,784,500 |
| 2024/09/05 | 981 | 993 | 967 | 971 | -9 | -0.9% | 660,500 |
| 2024/09/04 | 973 | 1,003 | 971 | 980 | -16 | -1.6% | 1,279,700 |
| 2024/09/03 | 1,000 | 1,003 | 984 | 996 | ±0 | ±0% | 748,400 |
| 2024/09/02 | 1,029 | 1,045 | 989 | 996 | -50 | -4.8% | 1,641,700 |
| 2024/08/30 | 992 | 1,051 | 973 | 1,046 | +51 | +5.1% | 1,591,600 |
| 2024/08/29 | 989 | 1,012 | 975 | 995 | +5 | +0.5% | 630,100 |
| 2024/08/28 | 1,004 | 1,007 | 985 | 990 | -21 | -2.1% | 985,500 |
| 2024/08/27 | 1,037 | 1,037 | 1,003 | 1,011 | -28 | -2.7% | 682,300 |
| 2024/08/26 | 1,017 | 1,040 | 995 | 1,039 | +28 | +2.8% | 1,035,200 |
| 2024/08/23 | 1,000 | 1,023 | 992 | 1,011 | +14 | +1.4% | 992,500 |
| 2024/08/22 | 1,018 | 1,029 | 992 | 997 | -26 | -2.5% | 1,308,500 |
| 2024/08/21 | 1,074 | 1,086 | 1,022 | 1,023 | -73 | -6.7% | 1,765,400 |
| 2024/08/20 | 1,031 | 1,100 | 1,020 | 1,096 | +73 | +7.1% | 1,703,100 |
| 2024/08/19 | 1,015 | 1,130 | 1,010 | 1,023 | +22 | +2.2% | 3,247,100 |
| 2024/08/16 | 1,041 | 1,049 | 997 | 1,001 | -39 | -3.8% | 1,177,200 |
| 2024/08/15 | 991 | 1,047 | 983 | 1,040 | +49 | +4.9% | 1,344,500 |
| 2024/08/14 | 1,006 | 1,012 | 982 | 991 | -18 | -1.8% | 823,200 |
| 2024/08/13 | 975 | 1,016 | 952 | 1,009 | +34 | +3.5% | 1,116,500 |
201～
250
件表示中 / 2534件
類似銘柄と比較する
現在ご覧いただいている「サンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| サンバイオ | 250,600円 | - | - | 0.00% | - | 116.07倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
| ペプチド | 151,600円 | +5.0% | +1.5% | 0.00% | 12.97倍 | 3.65倍 |
|
東大発のペプチド創薬ベンチャーの雄。海外製薬大手との提携多数。買収で放射性医薬品に参入 |
| キッセイ薬 | 429,000円 | +3.6% | - | 2.80% | 14.46倍 | 0.85倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
| 鳥居薬 | 633,000円 | +7.1% | -35.0% | 0.00% | 52.34倍 | 1.45倍 |
|
ＪＴ傘下。皮膚疾患や腎・透析、花粉症薬などアレルゲン領域に強み。塩野義製薬がＴＯＢ実施 |
| 科研薬 | 386,600円 | -6.4% | -71.8% | 4.91% | 43.06倍 | 0.96倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の２本柱。後発品も展開 |
市場注目の銘柄
チャート関連のコラム
